 LEXINGTON, Mass., Sept. 09, 2021 GLOBE NEWSWIRE -- T2 Biosystems, Inc. NASDAQ:TTOO, a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2TM Panela molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infectionsis capable of detecting the Mu B.1.621 and Iota B.1.526 variants of the SARS-CoV-2 virus, which were recently confirmed to be present in the United States. 